ImpediMed

ImpediMed Equity Ratio

The Equity Ratio of ImpediMed (IPD.AX) as of Oct 30, 2026 is 29.39 %. In the previous year, Equity Ratio was 49.20 % — a change of -40.26% (lower).

Equity Ratio

29.39 %

YoY

-40.26%

Last updated:

Equity Ratio of ImpediMed is 2026 29.39 % . Equity Ratio of ImpediMed was 2025 49.20 % . It decreases by -40.26% lower compared to the previous year.

The ImpediMed Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2019
69.90 AUD
Jan 1, 2020
82.75 AUD
Jan 1, 2021
74.59 AUD
Jan 1, 2022
86.96 AUD
Jan 1, 2023
88.57 AUD
Jan 1, 2024
86.71 AUD
Jan 1, 2025
49.20 AUD
Jan 1, 2026
29.39 AUD
The ImpediMed Equity Ratio history
YEAREquity RatioYoY
29.39 %-40.26%
49.20 %-43.26%
86.71 %-2.10%
88.57 %+1.85%
86.96 %+16.58%
74.59 %-9.86%
82.75 %+18.38%
69.90 %-18.84%
86.13 %-5.74%
91.38 %-2.92%
94.13 %+2.45%
91.88 %+1.56%
90.47 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Equity Ratio of ImpediMed is 29.39 % in 2026.

Equity Ratio of ImpediMed changed from 49.20 % to 29.39 %, representing a -40.26% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio ImpediMed since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's ImpediMed with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — ImpediMed

All Key Metrics — ImpediMed